J
John P. Sfakianos
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 227
Citations - 5125
John P. Sfakianos is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Bladder cancer & Medicine. The author has an hindex of 28, co-authored 168 publications receiving 3471 citations. Previous affiliations of John P. Sfakianos include State University of New York System & Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Gold nanoshell-localized photothermal ablation of prostate tumors in a clinical pilot device study
Ardeshir R. Rastinehad,Harry Anastos,Ethan Wajswol,Jared S. Winoker,John P. Sfakianos,Sai K. Doppalapudi,Michael R. Carrick,Cynthia J. Knauer,Bachir Taouli,Sara Lewis,Ashutosh K. Tewari,Jon A. Schwartz,Steven E. Canfield,Arvin K. George,Jennifer L. West,Naomi J. Halas +15 more
TL;DR: This treatment protocol appears to be feasible and safe in men with low- or intermediate-risk localized prostate cancer without serious complications or deleterious changes in genitourinary function and results in greatly reduced patient morbidity and improved functional outcomes.
Journal ArticleDOI
Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma
Eliezer M. Van Allen,Kent W. Mouw,Philip H. Kim,Gopa Iyer,Nikhil Wagle,Hikmat Al-Ahmadie,Cong Zhu,Irina Ostrovnaya,Gregory V. Kryukov,Kevin W O'Connor,John P. Sfakianos,Ilana Rebecca Garcia-Grossman,Jaegil Kim,Elizabeth A. Guancial,Richard Martin Bambury,Samira Bahl,Namrata Gupta,Deborah N. Farlow,Angela Qu,Sabina Signoretti,Justine A. Barletta,Victor E. Reuter,Jesse S. Boehm,Michael S. Lawrence,Gad Getz,Philip W. Kantoff,Bernard H. Bochner,Toni K. Choueiri,Dean F. Bajorin,David B. Solit,Stacey Gabriel,Alan D. D'Andrea,Levi A. Garraway,Levi A. Garraway,Jonathan E. Rosenberg,Jonathan E. Rosenberg +35 more
TL;DR: Somatic ERCC2 mutations correlate with complete response to cisplatin-based chemosensitivity in muscle-invasive urothelial carcinoma, and clinically identified mutations lead to cisPlatin sensitivity in vitro.
Journal ArticleDOI
The effect of age and gender on bladder cancer: a critical review of the literature.
Shahrokh F. Shariat,John P. Sfakianos,John P. Sfakianos,Michael J. Droller,Pierre I. Karakiewicz,Siegfried Meryn,Bernard H. Bochner +6 more
TL;DR: While men are three to four times more likely to develop UCB than women, women present with more advanced disease and have worse survival rates, and Epidemiological and mechanistic molecular studies should be encouraged to design, analyse and report gender‐ and age‐specific associations.
Journal ArticleDOI
Genomic Characterization of Upper Tract Urothelial Carcinoma
John P. Sfakianos,John P. Sfakianos,Eugene K. Cha,Gopa Iyer,Gopa Iyer,Sasinya N. Scott,Emily C. Zabor,Ronak Shah,Qinghu Ren,Aditya Bagrodia,Philip H. Kim,A. Ari Hakimi,Irina Ostrovnaya,Ricardo Ramirez,Aphrothiti J. Hanrahan,Neil Desai,Arony Sun,Patrizia Pinciroli,Jonathan E. Rosenberg,Jonathan E. Rosenberg,Guido Dalbagni,Guido Dalbagni,Nikolaus Schultz,Dean F. Bajorin,Dean F. Bajorin,Victor E. Reuter,Michael F. Berger,Michael F. Berger,Bernard H. Bochner,Bernard H. Bochner,Hikmat Al-Ahmadie,David B. Solit,David B. Solit,Jonathan A. Coleman,Jonathan A. Coleman +34 more
TL;DR: High-grade UTUC tumors display a spectrum of genetic alterations similar to high-grade UCB, but there were significant differences in the prevalence of several recurrently mutated genes including HRAS, TP53, and RB1.
Journal ArticleDOI
EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer.
Li Wang,Li Wang,Abdel Saci,Péter Szabó,Scott D. Chasalow,Mireia Castillo-Martin,Josep Domingo-Domenech,Arlene O. Siefker-Radtke,Padmanee Sharma,John P. Sfakianos,Yixuan Gong,Ana Dominguez-Andres,William Oh,David J. Mulholland,Alex Azrilevich,Liangyuan Hu,Carlos Cordon-Cardo,Hélène Salmon,Nina Bhardwaj,Jun Zhu,Matthew D. Galsky +20 more
TL;DR: It is demonstrated that in patients with T-cell infiltrated tumors, higher EMT/stroma-related gene expression is associated with lower response rates and shorter progression-free and overall survival, suggesting a stroma-mediated source of immune resistance in urothelial cancer and providing rationale for co-targeting PD-1 and stromal elements.